Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Letter
  • Published:

The carrier frequency of the BRCA2 6174delT mutation among Ashkenazi Jewish individuals is approximately 1%

Abstract

Certain germline mutations in either BRCA1 or BRCA2 confer a lifetime risk of developing breast cancer that may approach 90% 1–3. The BRCA1 185delAG mutation was found in 20% and the BRCA2 6174delT mutation in 8% of Ashkenazi Jewish women with early-onset breast cancer4–6. The 185delAG mutation was observed in 0.9% of 858 Ashkenazi Jews unselected for a personal or family history of cancer7. Assuming comparable age-specific penetrances, a carrier frequency of 0.3% was estimated for the 6174delT BRCA2 mutation6. To test this hypothesis, we performed a population survey of 1,255 Jewish individuals. In two independent groups, a prevalence of approximately 1 % (C.I. 0.6–1.5) was observed for the 6174delT mutation. The relative risk of developing breast cancer by age 42 was estimated to be 9.3 (C.I. 2.5–22.5) for6174delT, compared to 31 (C.I. 11–77) for 185delAG. Analysis of 107 Ashkenazi Jewish women with breast cancer and a family history of breast or ovarian cancer confirmed a four-fold greater prevalence for the BRCA1 185delAG mutation compared to the BRCA2 6174delT mutation. Our findings suggest a difference in cumulative lifetime penetrance for the two mutations. Genetic counseling for the one in 50 Ashkenazi Jewish individuals harbouring specific germline mutations in BRCA1 or BRCA2 must be tailored to reflect the different risks associated with the two mutations.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Easton, D. et al. Genetic linkage analysis in familial breast and ovarian cancer: results from 214 families. Am. J. Hum Genet. 52, 678–701 (1993).

    CAS  PubMed  PubMed Central  Google Scholar 

  2. Wooster, R. et al. Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12–13. Science 265, 2088–2090 (1994).

    Article  CAS  Google Scholar 

  3. Miki, Y. et al. A strong candidate gene for the breast and ovarian cancer susceptibility gene BRCA1. Science 266, 66–71 (1994).

    Article  CAS  Google Scholar 

  4. FitzGerald, M.G. et al. Germ-line BRCA1 mutations in Jewish and non-Jewish women with early-onset breast cancer. N. Engl. J. Med. 334, 143–149 (1996).

    Article  CAS  Google Scholar 

  5. Offit, K. et al. Germline BRCA1 185delAG mutations in Jewish women affected by breast cancer. Lancet 347, 1643–1645 (1996).

    Article  CAS  Google Scholar 

  6. Neuhausen, S. et al. Recurrent BRCA2 6174delT mutations in Ashkenazi Jewish women affected by breast cancer. Nature Genet. 13, 126–128 (1996).

    Article  CAS  Google Scholar 

  7. Struewing, J.P. et al.The carrier frequency of the BRCA1 185delAG mutation is approximately 1 percent in Ashkenazi Jewish individuals. Nature Genet. 11, 198–200 (1995).

    Article  CAS  Google Scholar 

  8. Wooster, R. et al. Identification of the breast cancer susceptibility gene BRCA2. Nature 378, 789–792 (1995).

    Article  CAS  Google Scholar 

  9. Tavtigian, S.V. et al. The BRCA2 gene and mutations in 13q-linked kindreds. Nature Genet. 12, 333–337 (1996).

    Article  CAS  Google Scholar 

  10. Simard, J. et al. Common origins of BRCA1 mutations in Canadian breast and ovarian cancer families. Nature Genet. 8, 392–398 (1994).

    Article  CAS  Google Scholar 

  11. Struewing, J.P. et al Detection of eight BRCA1 mutations in 10 breast ovarian cancer families including 1 family with male breast cancer Am.J.Hum Genet. 57, 1–7 (1995).

    Article  CAS  Google Scholar 

  12. Tonin, P. et al.BRCA1 mutations in Ashkenazi Jewish Women. Am. J. Hum Genet. 57, 189 (1995).

    CAS  PubMed  PubMed Central  Google Scholar 

  13. Berman, D.B., Wagner-Costalas, J., Schultz, D.C., Lynch, H.T., Daly, M. & Godwin, A.K. Two distinct origins of a common BRCA1 mutation in breast ovarian cancer families: a genetic study of 15185delAG-mutation kindreds. Am.J.Hum Genet 58, 1166–1176 (1996).

    CAS  PubMed  PubMed Central  Google Scholar 

  14. Neuhausen, S.L. et al. Haplotypeand phenotype analysis of six recurrent BRCA1 mutations in 61 families: results of an international study. Am. J. Hum Genet. 58, 271–280, (1996).

    CAS  PubMed  PubMed Central  Google Scholar 

  15. Kronn, D., Oddoux, C., Phillips, J. & Ostrer, H. The frequency of carriers for Canavan disease in the metropolitan New York Ashkenazi Jewish population. Am. J. Hum Genet. 57, 1250–1252, (1995).

    CAS  PubMed  PubMed Central  Google Scholar 

  16. Oddoux, C. et al. Prenatal diagnostic testing for familial dysautonomia using linked genetic markers. Prenat. Diagn. 15, 817–826 (1995).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Harry Ostrer.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Oddoux, C., Struewing, J., Clayton, C. et al. The carrier frequency of the BRCA2 6174delT mutation among Ashkenazi Jewish individuals is approximately 1%. Nat Genet 14, 188–190 (1996). https://doi.org/10.1038/ng1096-188

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ng1096-188

This article is cited by

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing